×
Merck Receivables 2010-2024 | MKGAF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck receivables for the quarter ending June 30, 2024 were
$5.085B
, a
1.18% decline
year-over-year.
Merck receivables for 2023 were
$4.845B
, a
0.85% increase
from 2022.
Merck receivables for 2022 were
$4.804B
, a
1.86% decline
from 2021.
Merck receivables for 2021 were
$4.896B
, a
14.56% increase
from 2020.
View More
Merck Receivables 2010-2024 | MKGAF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merck receivables for 2023 were
$4.845B
, a
0.85% increase
from 2022.
Merck receivables for 2022 were
$4.804B
, a
1.86% decline
from 2021.
Merck receivables for 2021 were
$4.896B
, a
14.56% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$89B
Takeda Pharmaceutical (TAK)
$47.2B
Astellas Pharma (ALPMY)
$22.1B
Summit Therapeutics (SMMT)
$17.8B
Sandoz Group AG (SDZNY)
$17.6B
United Therapeutics (UTHR)
$15.2B
Shionogi (SGIOY)
$13.1B
Neurocrine Biosciences (NBIX)
$12.1B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Corcept Therapeutics (CORT)
$4.4B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Dyne Therapeutics (DYN)
$3.4B
PTC Therapeutics (PTCT)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B
NewAmsterdam Pharma (NAMS)
$1.4B